MediWound Ltd.

As of September 12, 2025, MediWound Ltd. shows a mildly bearish trend with bearish weekly and monthly MACD and KST indicators, underperforming the S&P 500 year-to-date and over the past year.

As of August 6, 2020, MediWound Ltd. is considered overvalued and risky due to poor financial metrics, including a high Price to Book Value of 7.46 and negative EV to EBIT and EV to EBITDA ratios, indicating significant struggles compared to its peers.

As of August 6, 2020, MediWound Ltd. is considered overvalued and has shifted to a risky valuation grade due to negative earnings, significant losses, and poor financial ratios compared to its peers, alongside a recent stock decline of 7.32%.

As of June 20, 2025, the trend is mildly bullish with supportive indicators like a bullish MACD and moving averages, but mixed signals from the KST and Dow Theory suggest potential volatility ahead.

As of March 2022, the management team of MediWound Ltd. includes Mr. Stephen Wills (Executive Chairman), Mr. David Fox, Mr. Ofer Gonen, Mr. Samuel Moed, Mr. Assaf Segal (all Directors), and Dr. Vickie Driver (Independent Director). They oversee the company's strategic direction and operations.

MediWound Ltd. is an Israeli biopharmaceutical company focused on developing and commercializing products for severe burns, chronic wounds, and connective tissue disorders. As of March 2025, it reported net sales of $4 million and a net loss of $1 million, with a market cap of $213.78 million.

As of Jun 18, MediWound Ltd. has a market capitalization of 213.78 million, with net sales of 19.22 million and a net profit of -21.23 million over the latest four quarters. Shareholder's funds are 31.15 million, and total assets are 73.50 million.